Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04930094 · ClinicalTrials.gov registry record · Phase 3
Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 354
- Enrollment target
NCT04930094 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 354 participants.
The verdict
NCT04930094, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 354 participants
- Enrollment target
Study Summary
This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
Interventions
- OTHER Placebo
- BIOLOGICAL Secukinumab 300 mg
- BIOLOGICAL Secukinumab 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 354 participants |
| Start Date | 2021-10-06 |
| Est. Completion | 2026-02-18 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04930094
The ClinicalTrials.gov registry entry for NCT04930094 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 354 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04930094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04930094 about?
NCT04930094 is a clinical study titled "Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Giant Cell Arteritis (GCA)". This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with giant cell arteritis (GCA)
What is the current status of trial NCT04930094?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 354 participants. The study started on 2021-10-06. Estimated completion is 2026-02-18.
What interventions are being tested in trial NCT04930094?
The interventions under investigation include: Placebo (OTHER), Secukinumab 300 mg (BIOLOGICAL), Secukinumab 150 mg (BIOLOGICAL).
Who is sponsoring clinical trial NCT04930094?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.